Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis.
It is known that in various pathophysiological conditions, reactive oxidants cause DNA strand breakage and subsequent activation of the nuclear enzyme poly(ADP ribose) polymerase (PARP). Activation of PARP results in cellular dysfunction. We hypothesized that pharmacological inhibition of PARP reduces the damage in the ovine model of acute lung injury (ALI). After smoke inhalation, Pseudomonas aeruginosa (5 x 109 cfu/kg) was instilled into both lungs. All of the animals were mechanically ventilated with 100% O2. The infusion of the PARP inhibitor (INO-1001, n = 6) began 1 h after the injury and thereafter through 24 h (3 mg bolus + 0.3 mg/kg/h, i.v.). Control animals (n = 6) were treated with saline. Sham injury animals (n = 8) received sham smoke and were mechanically ventilated in the same fashion. One-half of those sham animals (n = 4) were given the same dose of INO-1001. PaO2/FiO2 ratio at 24 h in saline and in the INO-1001-treated groups were 95 +/- 22 and 181 +/- 22, respectively (P < 0.05). Peak airway pressure at 24 h in the saline- and INO-1001-treated groups was 32.6 +/- 3.0 and 24.4 +/- 2.2, respectively (P < 0.05). Pulmonary shunt fraction was also significantly attenuated. INO-1001 treatment reduced pulmonary histological injury and attenuated poly (ADP-ribose) accumulation in the lung. In conclusion, inhibition of PARP improved the ALI after smoke inhalation and pneumonia. The results suggest that the activation of PARP plays a role in the pathophysiology of ALI in sheep.
Murakami
Kazunori
K
Department of Anesthesiology, The University of Texas Medical Branch and Shriners Burns Hospital, Galveston, Texas, 77555, USA. kmurakam@infoseek.to
Enkhbaatar
Perenlei
P
Shimoda
Katsumi
K
Cox
Robert A
RA
Burke
Ann S
AS
Hawkins
Hal K
HK
Traber
Lillian D
LD
Schmalstieg
Frank C
FC
Salzman
Andrew L
AL
Mabley
Jon G
JG
Komjáti
Katalin
K
Pacher
Pál
P
Zsengellér
Zsuzsanna
Z
Szabó
Csaba
C
Traber
Daniel L
DL
D000818:Animals; D000991:Antithrombins / Q000378:metabolism; D004249:DNA Damage; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D007150:Immunohistochemistry; D007211:Indoles / Q000494:pharmacology; D015227:Lipid Peroxidation; D008168:Lung / Q000473:pathology; D008315:Malondialdehyde / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018805:Sepsis / Q000188:drug therapy*; D012756:Sheep; D013997:Time Factors; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000378:metabolism
D000991:Antithrombins; D004791:Enzyme Inhibitors; D006454:Hemoglobins; C491685:INO 1001; D007211:Indoles; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D012333:RNA, Messenger; D009569:Nitric Oxide; C002744:3-nitrotyrosine; D014443:Tyrosine; D008315:Malondialdehyde; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II